arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Edgewise Therapeutics, Inc.

EWTX Health Care Biotechnology: Pharmaceutical Preparations
$43.07
Today
as of Sep 4, 16:48 ET
Last 30 days +6.74% Jul 28 → Sep 04
$37.74 $40.07 $42.41 $44.75 $47.08 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$41.73
High
$43.33
Low
$41.60
Volume
$819,952
Avg Vol
$1M
Mkt Cap
$4.7B
P/E (TTM)
—
Beta
—
52w High
$48.40
52w Low
$13.69
Div Yield
—
Shares Out
$108M

Recent Press Releases & News last 60 days · 9 items

Sep 2 · 12:00 PR PR Newswire
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Aug 24 · 12:00 PR PR Newswire
Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026
Aug 7 · 10:08 MT Newswires
Wedbush Adjusts Pt on Edgewise Therapeutics to $53 From $52, Maintains Outperform Rating
▸ Show all 9 press releases & news Free account →

Overview

52-week range
$14
$48
85% of range
Avg surprise (last 3)
+10.5%
Avg reaction (last 2)
-1.3%
50% positive
Latest IV / EM
64%
EM ±10.0% · $43 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.53$-0.48$-0.43$-0.38$-0.33 Actual $-0.36Actual $-0.34Actual $-0.41Actual $-0.33Actual $-0.34Actual $-0.36Actual $-0.43Est $-0.45Actual $-0.34Est $-0.42Actual $-0.39Actual $-0.46Est $-0.50Actual $-0.53 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-57M$-52M$-47M$-41M$-36M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.53 — — — — financials
Thu May 7, 2026Mar/2026 $-0.46 $-0.50 +8.0% -7.0% -3.8% earnings
Tue Sep 30, 2025Sep 2025 $-0.39 — — — — financials
Thu Aug 7, 2025Jun/2025 $-0.34 $-0.42 +19.1% — — earnings
Thu May 8, 2025Mar/2025 $-0.43 $-0.45 +4.4% — +1.2% earnings
Mon Sep 30, 2024Sep 2024 $-0.36 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.34 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.33 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.41 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.34 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.36 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-62M$-54M—$-47M$-43M$-46M—$-40M
Net income$-57M$-49M—$-41M$-36M$-41M—$-34M
EPS (diluted)$-0.53$-0.46—$-0.39$-0.34$-0.43—$-0.36

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$72M$33M$61M$46M$43M$50M$42M$45M
Inventory————————
Total current assets$472M$510M$543M$574M$603M$443M$475M$499M
Total assets$480M$519M$553M$583M$613M$454M$487M$511M
Long-term debt————————
Total liabilities$32M$25M$30M$25M$24M$25M$28M$22M
Total equity$448M$493M$522M$559M$589M$430M$459M$489M

Implied volatility — last 90 days

58%129%199%269%340% Jun 07 — IV 98% · EM ±13.6%Jun 08 — IV 103% · EM ±13.6%Jun 09 — IV 121% · EM ±15.1%Jun 10 — IV 102% · EM ±12.1%Jun 11 — IV 149% · EM ±16.5%Jun 12 — IV 130% · EM ±13.3%Jun 15 — IV 174% · EM ±12.6%Jun 16 — IV 269% · EM ±15.9%Jun 17 — IV 340% · EM ±14.2%Jun 19 — IV 69% · EM ±15.1%Jun 22 — IV 71% · EM ±14.9%Jun 23 — IV 65% · EM ±13.3%Jun 24 — IV 70% · EM ±14.0%Jun 25 — IV 65% · EM ±12.8%Jun 26 — IV 63% · EM ±12.1%Jun 29 — IV 70% · EM ±12.4%Jun 30 — IV 59% · EM ±10.1%Jul 01 — IV 80% · EM ±13.3%Jul 02 — IV 79% · EM ±12.7%Jul 03 — IV 81% · EM ±12.7%Jul 06 — IV 64% · EM ±8.9%Jul 07 — IV 78% · EM ±10.3%Jul 08 — IV 92% · EM ±11.5%Jul 09 — IV 87% · EM ±10.3%Jul 10 — IV 85% · EM ±9.4%Jul 13 — IV 96% · EM ±8.1%Jul 15 — IV 205% · EM ±12.1%Jul 16 — IV 307% · EM ±12.8%Jul 20 — IV 73% · EM ±17.1%Jul 21 — IV 69% · EM ±16.0%Jul 22 — IV 71% · EM ±16.3%Jul 23 — IV 69% · EM ±15.6%Jul 24 — IV 72% · EM ±15.9%Jul 27 — IV 63% · EM ±13.2%Jul 28 — IV 68% · EM ±14.0%Jul 29 — IV 79% · EM ±15.9%Jul 30 — IV 70% · EM ±13.6%Jul 31 — IV 60% · EM ±11.5%Aug 03 — IV 72% · EM ±12.8%Aug 04 — IV 84% · EM ±14.5%Aug 05 — IV 75% · EM ±12.6%Aug 06 — IV 82% · EM ±13.2%Aug 07 — IV 70% · EM ±10.9%Aug 10 — IV 83% · EM ±11.4%Aug 11 — IV 72% · EM ±9.5%Aug 12 — IV 85% · EM ±10.6%Aug 13 — IV 72% · EM ±8.5%Aug 14 — IV 98% · EM ±10.9%Aug 17 — IV 101% · EM ±8.5%Aug 18 — IV 100% · EM ±7.3%Aug 19 — IV 183% · EM ±10.8%Aug 20 — IV 277% · EM ±11.6%Aug 24 — IV 78% · EM ±16.2%Aug 25 — IV 68% · EM ±13.9%Aug 26 — IV 72% · EM ±14.4%Aug 27 — IV 70% · EM ±13.8%Aug 28 — IV 75% · EM ±14.4%Aug 31 — IV 74% · EM ±13.0%Sep 01 — IV 79% · EM ±13.6%Sep 02 — IV 72% · EM ±12.1%Sep 03 — IV 72% · EM ±11.6%Sep 04 — IV 64% · EM ±10.0%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in